Roche Holdings AG on Monday shared results from the phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients. Trial Misses Primary Goal The trial ...
Medicus Pharma (NASDAQ:MDCX) said on Monday that new analysis of data from a mid-stage clinical trial of its SkinJect ...
A group of natural compounds attracting attention for their anti-aging potential has a dark side. New research shows how a ...
A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.
During the Miami Breast Cancer Conference, CURE discussed ADCs with Dr. Kevin Kalinsky.
Discover the impact of digital pathology on drug discovery and biomarker research this International Women’s Day with Dr ...
The Biologics Price Competition and Innovation Act of 2009 created the abbreviated approval pathway that biosimilars rely on, and the FDA has approved 82 biosimilars to date, with the new guidance is ...
Scientists at Oregon Health & Science University have developed a new molecule that could open the door to treating triple-negative breast cancer, one of the most aggressive and difficult-to-treat ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...
A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...
Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...
Dr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results